Brent Burnette, MD
Gastroenterology · Las Vegas, NVNPI 1699989251
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 29.5% of the total. That places this record below the midpoint for gastroenterology clinicians in NV, where the typical reported total is $3,212.
Across 162 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$298
- Gilead$238
- Pfizer$227
- Boston Scientific$204
- Daiichi Sankyo Inc.$156
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,435100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $1,014 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $298 |
| Gilead | 11 | $238 |
| Pfizer | 7 | $227 |
| Boston Scientific | 6 | $204 |
| Daiichi Sankyo Inc. | 1 | $156 |
| Foundation Medicine, Inc. | 1 | $148 |
| SPR Therapeutics, Inc | 1 | $143 |
| Johnson & Johnson | 15 | $132 |
| QOL Medical, LLC | 9 | $105 |
| Medtronic | 1 | $102 |
| Bard Peripheral Vascular, Inc. | 1 | $99 |
| Ferring Pharmaceuticals Inc. | 4 | $73 |
| Aimmune Therapeutics, Inc. | 3 | $69 |
| Endogastric Solutions, Inc | 1 | $63 |
| UCB, Inc. | 2 | $53 |
| Celltrion USA Inc. | 2 | $43 |
| Sanofi | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Ironwood Pharmaceuticals, Inc | 2 | $34 |
| Braintree Laboratories, Inc. | 2 | $31 |
| Merck | 2 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Biocon Biologics Inc | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$156
- FOUNDATIONONE$148
- FOUNDATIONONE HEME$148
- FOUNDATIONONE CDX$148
- FOUNDATIONFOCUS$148
- FOUNDATIONONE LIQUID CDX$148
- SPRINT PNS System$143
- Skyrizi$131
- XELJANZ$116
- INTERSTIM$102
How this compares
$3,435 in reported general payments places this provider in the 50th percentile of 103 gastroenterology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 27 | $711,700 |
| Humira(Cf) PenAdalimumab | 29 | $238,766 |
| LinzessLinaclotide | 45 | $44,469 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 52 | $3,485 |
| Omeprazole | 269 | $2,925 |
| Pantoprazole Sodium | 61 | $791 |
| Esomeprazole Magnesium | 16 | $764 |
| Desipramine Hcl | 15 | $699 |
| CholestyramineCholestyramine (With Sugar) | 15 | $660 |
| Ondansetron OdtOndansetron | 12 | $396 |
| Famotidine | 45 | $345 |
| Spironolactone | 11 | $88 |
| Trazodone Hcl | 13 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $132 | $711,70027 claims |
| AbbVieLinzess | $1,014 | $44,46945 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 103 gastroenterology providers in Nevada.
Other gastroenterology in Las Vegas
- Christian StoneLas Vegas$1.1M
- James HanLas Vegas$47K
- Filippo CremoniniLas Vegas$36K
- Vijay JayaramanLas Vegas$28K
- Gary ChenLas Vegas$27K
- David ShihLas Vegas$26K
- Noel FajardoLas Vegas$22K
- Frank FarisLas Vegas$14K
- Tarek AmmarLas Vegas$14K
- Eladio CarreraLas Vegas$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.